Iron deficiency is one of the most prevalent nutritional deficiency disorders in the world, and a major cause of anemia. About 2 billion people were reported to suffer from anemia, including high numbers among women and children; the numbers are even higher for non-anemic, iron deficiency patients. The traditional solution, oral iron supplementation, has poor efficacy and damaging side effects. Low efficiency of iron transport is likely a key cause of both the disorder and the problems associated with the current treatment. Increasing iron uptake effficiency appears to be the key to significantly improving the current treatment.
Using a unique assay, Dr. Min Han's team has discovered an unexpected and striking role of Enterobactin (Ent) in supporting growth and the labile iron pool in C. elegans. Ent, a compound with high affinity for iron (Fe3+), is produced and used by certain bacteria (including gut microbes) to acquire iron from the environment. This new work has demonstrated that ferric-Ent is taken up by the host and is bioavailable. Mechanistically, the Han lab found, in both C. elegans and human cells, that Ent brings Fe3+ into the mitochondria through binding to the alpha subunit of the ATP synthase. The newly discovered role of enterobactin in promoting mitochondrial iron uptake and animal health may present a potential transformative treatment of iron deficiency and related anemia. In tests using C. elegans, Ent dramatically improved the iron level in animals fed a low iron diet.
According to Credence Research (credenceresearch.com/press/global-iron-supplements-market), the global iron supplement market was over $3 billion in 2015 and expected to reach $6.35 billion by 2025. Ent will not be used to replace iron supplementation. Rather, Ent supplementation is expected to dramatically increase the efficiency of iron uptake, which should drastically reduce the effective dosage of iron supplementation and the acompanying side effects. Therefore, Ent supplementation is potentially an important medical treatment needed for the vast majority of the patients who take iron supplement to treat the disorder, which points to a huge potential market.
Dr. Han is currently testing the effectiveness of Ent in treating iron deficiency using mammlian models. He also plans to conduct medicinal chemistry work that will entail design and synthesis of Enterobactin analogues, followed by key in vivo studies. Currently, he is seeking business advisors and partners who could help navigate further development of the technology and the product.